FDA Approves Gardasil for Males

--

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--
Oct 16, 2009

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recommend administration of Gardasil for use in males, as well as public funding through the U.S. Centers for Disease Control and Prevention (CDC) contract. These votes are expected on October 21.

View the complete article